Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael McEntire

Pain Medicine Rochester, MN Medical Doctor

NPI 1477875094 CMS profile 860593

200 1St St Sw, Ste 1A, Rochester, MN 55905

Open in the dashboard

General payments

$69,728

823 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael McEntire of Rochester, MN is reported in the CMS Open Payments database as having received $69,728 across 823 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,766 108
2024 General $18,763 129
2023 General $17,627 126
2022 General $9,249 127
2021 General $9,940 110
2020 General $1,849 101
2019 General $3,535 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael McEntire
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Michael McEntire were reported at $8,766. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Michael McEntire Pain Medicine median Middle half National median
2019 $3,535 $498 $126–$1,682 $163
2020 $1,849 $284 $80–$910 $114
2021 $9,940 $399 $112–$1,219 $132
2022 $9,249 $455 $137–$1,484 $149
2023 $17,627 $484 $128–$1,495 $160
2024 $18,763 $498 $131–$1,540 $164
2025 $8,766 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $59,432 475 payments
  2. Boston Scientific Corporation $5,973 143 payments
  3. Medtronic USA, Inc. $2,884 140 payments
  4. SPR Therapeutics, Inc $565 5 payments
  5. Abbott Laboratories $223 14 payments
  6. TerSera Therapeutics LLC $129 9 payments
  7. Pfizer Inc. $112 18 payments
  8. Nevro Corp. $110 3 payments
  9. Horizon Therapeutics plc $106 6 payments
  10. Biodelivery Sciences International, Inc. $41 2 payments
  11. Other $153 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,200 13 payments
  2. Food and Beverage $17,158 759 payments
  3. Travel and Lodging $10,755 50 payments
  4. Consulting Fee $6,615 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $33,416 181 payments
  2. NVISION $2,800 1 payment
  3. VANTA ADAPTIVESTIM $2,615 70 payments
  4. SYNCHROMEDII $2,540 76 payments
  5. RESTORE $2,465 107 payments
  6. SPECTRA WAVEWRITER $1,902 35 payments
  7. INTELLIS $1,306 31 payments
  8. Intracept $1,005 4 payments
  9. OSTEOCOOL RF ABLATION SYSTEM $902 8 payments
  10. INCEPTIV $893 28 payments
  11. Other $6,099 285 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,120

Median for Anesthesiology: 322

Drug cost

$23,232

Median for Anesthesiology: $8,738

Branded share of claims

29.1%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 237 $4,705
Pregabalin Generic 111 $4,400
Celecoxib Generic 56 $3,310
Gabapentin Generic 141 $2,680
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 63 $1,291
Oxycodone Hcl Generic 41 $838
Naloxone Hcl Generic 12 $812
Tramadol Hcl Generic 97 $786
Tizanidine Hcl Generic 71 $697
Methocarbamol Generic 48 $573

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$150,435

Medicare's payments for the services billed

Medicare patients

455

Average age 74

Services billed

2,689

231 women, 224 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Depression 33%
Diabetes 27%
Ischemic heart disease 23%
Chronic kidney disease 22%
Osteoporosis 18%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

823 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record